Phaseline

Companies › Inventiva Pharma

Inventiva Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Gastroenterology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lanifibranor (IVA337)
Peroxisome proliferator-activated receptor agonist
PPARG, PPARA, PPARDPhase 3NASH - Nonalcoholic SteatohepatitisSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04849728Lanifibranor (IVA337)Phase 3NASH - Nonalcoholic SteatohepatitisGastroenterologySep 2027

From the company's SEC filings

Cash of 97m EUR on 2024-12-31; operating cash outflow about 86m EUR a year; runway about 14 months at that burn, to Feb 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PPARG (1) PPARA (1) PPARD (1)

Companies with the same targets

RDC Clinical Zydus Therapeutics Ipsen Flare Therapeutics Boryung Pharmaceutical Minoryx Therapeutics Dong Wha Pharmaceutical Kowa Company Gilead Sciences

Companies built like this

Zydus Therapeutics Elgan Pharma Cinclus Pharma Holding Norgine Green Cross Wellbeing

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.